【百利天恒(688506.SH)：BL-B01D1用于局部晚期或转移性三阴乳腺癌III期临床试验完成首例受试者入组】智通财经APP讯，百利天恒(688506.

智通财经07-03

【百利天恒(688506.SH)：BL-B01D1用于局部晚期或转移性三阴乳腺癌III期临床试验完成首例受试者入组】智通财经APP讯，百利天恒(688506.SH)公告，公司自主研发的创新生物药注射用BL-B01D1(EGFR×HER3-ADC)单药用于既往经紫杉烷类治疗失败的不可手术切除的局部晚期或转移性三阴乳腺癌的III期临床试验已于近日完成首例受试者入组。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2448349104?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-03 20:10","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2448349104","market":"us","top_or_hot":-1,"title":"【百利天恒(688506.SH)：BL-B01D1用于局部晚期或转移性三阴乳腺癌III期临床试验完成首例受试者入组】智通财经APP讯，百利天恒(688506.","media":"智通财经","content":"<div>\n<p>【百利天恒(688506.SH)：BL-B01D1用于局部晚期或转移性三阴乳腺癌III期临床试验完成首例受试者入组】智通财经APP讯，百利天恒(688506.SH)公告，公司自主研发的创新生物药注射用BL-B01D1(EGFR×HER3-ADC)单药用于既往经紫杉烷类治疗失败的不可手术切除的局部晚期或转移性三阴乳腺癌的III期临床试验已于近日完成首例受试者入组。</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=astock\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7x24快讯</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7x24快讯\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-03 20:10 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=astock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【百利天恒(688506.SH)：BL-B01D1用于局部晚期或转移性三阴乳腺癌III期临床试验完成首例受试者入组】智通财经APP讯，百利天恒(688506.SH)公告，公司自主研发的创新生物药注射用BL-B01D1(EGFR×HER3-ADC)单药用于既往经紫杉烷类治疗失败的不可手术切除的局部晚期或转移性三阴乳腺癌的III期临床试验已于近日完成首例受试者入组。</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=astock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1576","symbol_name":"医药外包概念","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","article_id":"2448349104","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2448349104","pubTimestamp":1720008655,"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【百利天恒(688506.SH)：BL-B01D1用于局部晚期或转移性三阴乳腺癌III期临床试验完成首例受试者入组】智通财经APP讯，百利天恒(688506.SH)公告，公司自主研发的创新生物药注射用","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159839":"生物药","688506":"百利天恒","BK1576":"医药外包概念","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","BL":"Blackline Inc.","BK1141":"生命科学工具和服务","III":"信息服务","BK1583":"高瓴概念","BK4023":"应用软件","03347":"泰格医药","BK4134":"信息科技咨询与其它服务","BK4080":"零售业房地产投资信托","BK4231":"零售房地产信托","ADC":"艾格里房产","BK0239":"医药制造","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC"},"translate_title":"[Baili Tianheng (688506. SH): BL-B01D1 for locally advanced or metastatic triple negative breast cancer phase III clinical trial completed the first subject enrollment] Zhitong","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159839":1,"688506":1,"03347":1,"ADC":1,"BL":1,"III":1},"content_text":"【百利天恒(688506.SH)：BL-B01D1用于局部晚期或转移性三阴乳腺癌III期临床试验完成首例受试者入组】智通财经APP讯，百利天恒(688506.SH)公告，公司自主研发的创新生物药注射用BL-B01D1(EGFR×HER3-ADC)单药用于既往经紫杉烷类治疗失败的不可手术切除的局部晚期或转移性三阴乳腺癌的III期临床试验已于近日完成首例受试者入组。","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2448349104"}